Jeffrey S Farrow, who serves as both Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), completed a sequence of equity transactions on June 16, 2026. The executive sold 14,396 shares of the company’s common stock. The transaction occurred at a price of $60.95 per share, resulting in a total value of approximately $877,436.
According to the official filing, the sale was not a discretionary move by Mr. Farrow. Instead, it was a "sell to cover" transaction mandated by the issuer to satisfy tax withholding obligations linked to the vesting and settlement of his Restricted Stock Units (RSUs). This structured approach to equity compensation is standard practice for managing tax liabilities associated with share-based pay.
The day prior, on June 15, 2026, Mr. Farrow acquired 27,881 shares of Tarsus Pharmaceuticals common stock. These shares were delivered through the settlement of vested RSUs. The underlying grant originated from a plan issued on April 24, 2023, under the company’s 2020 Stock Plan. The vesting schedule dictates that 25% of the grant vests annually on June 15th, a schedule that will continue through 2027.
Following the completion of these transactions, Mr. Farrow’s direct holdings in Tarsus Pharmaceuticals common stock stand at 56,801 shares. The company’s stock has demonstrated notable momentum, having risen to $62.58 following the transaction. This price level reflects a strong 52% return over the past year.
These insider movements coincide with recent financial reporting from Tarsus Pharmaceuticals. The company reported its Q1 2026 earnings, revealing performance that surpassed market forecasts. The company achieved an earnings per share (EPS) of -$0.16, which marked a positive surprise of 46.67% compared to the forecasted -$0.30. Additionally, Tarsus Pharmaceuticals’ revenue reached $162 million, exceeding the projected $153.12 million. These developments highlight the company’s ability to outperform market expectations.
Despite the positive earnings report, Tarsus Pharmaceuticals experienced a slight decrease in its stock price. The earnings results are a key focus for investors, as they provide insight into the company’s financial health. Analyst opinions and stock price movements were not detailed in the recent news. These updates are part of ongoing developments surrounding Tarsus Pharmaceuticals.
For deeper insights into TARS’s valuation and access to exclusive Pro Research Reports covering 1,400+ US stocks, visit InvestingPro.